March 8, 2016 - Curant COO, Marc O'Connor, in Managed Healthcare Executive - At its simplest, the top three factors impacting medication spending are the massive increases in number and cost of specialty medications, the backlog of generics awaiting FDA approval and lack of medication adherence. According to a recent presentation delivered to the Pharmaceutical […]
There is a spotlight trained on the constant tug of war currently ongoing between payer and manufacturers regarding at-risk negotiations and drug costs. In the background, pharmacists are frequently left solo to handle the prior authorization and to ensure patient access to necessary medication. According to a November 2015 report from The Pew Charitable Trusts, […]
When it comes to treating population health, there is nothing that can replace the value of a real-life, caring person inquiring about a patient’s feelings, opinions and thoughts in order to identify barriers to medication access and adherence. Why is that? The square root of population health is the health of the individual patient. We’ve […]
There were two prevailing topics that dominated this year’s 340B Coalition Winter Conference: mega-guidance and 340B entity audits. While these terms are not mutually exclusive, they each received significant airtime throughout the conference. The mystery of mega-guidance According to 340B Health, mega-guidance (aka omnibus guidance) is a ruling designed to be a ‘one-stop-shop’ of 340B-related […]
February 29, 2016 - Curant President and CEO, Patrick Dunham, with Curant Senior Director of Pharmacy, David Carver, in Becker's Healthcare - Population health has always seemed like a unicorn to me. Every day I witness exactly what is required to positively impact outcomes for patients with chronic conditions. There is no silver bullet, no patient […]
The increase of specialty drug costs is something that cannot be denied or ignored. According to a study done by the Kaiser Family Foundation and Truven Health Analytics, prescription drug spending accounts for 10% of the national spending on healthcare. The percentage is even higher for self-insured employers. Let’s talk about the two consequences, one […]
February 22, 2016 - Curant COO, Marc O'Connor, in Specialty Pharmacy Times - According to a November 2015 report from The Pew Charitable Trusts, Specialty Drugs and Health Care Costs, in 2014, less than 1% of all prescriptions were written for specialty drugs, yet they accounted for approximately 32% of total drug expenditures. And the […]
Medication is getting pricier. We know the facts – the Kaiser Family Foundation and Truven Health Analytics calculate prescription drug spending at 10% of the total national health spend. Want to hear an even more shocking statistic? Drug spending alone in employer health plans tops out at a whopping 19% of total spend. There is […]
February 9, 2016 - Curant COO, Marc O'Connor, in Specialty Pharmacy Times - The meteoric rise of specialty drug cost has been well-documented and appropriately lambasted, at least in some circumstances. According to a recent report by the Kaiser Family Foundation and Truven Health Analytics, prescription drug spending accounts for 10% of national spending on […]
Every winter 340B Health brings key healthcare stakeholders together to discuss new 340B program developments, brainstorm and network at the 340B Coalition Winter Conference. This event provides a terrific forum for education, discussion and insight into what’s working well with the program and where there are opportunities for improvement. As a leader in personalized medication […]
